seasonal intermittent preventive treatment for the prevention of anaemia and malaria in ghanaian children a randomized, placebo controlled trial季节性间歇性预防治疗预防贫血和疟疾在加纳孩子一项随机、安慰剂对照试验.pdfVIP

Seasonal Intermittent Preventive Treatment for the Prevention of Anaemia and Malaria in Ghanaian Children: A Randomized, Placebo Controlled Trial 1,2 1 3 4 2,5 1 Margaret Kweku , Dongmei Liu , Martin Adjuik , Fred Binka , Mahmood Seidu , Brian Greenwood , Daniel Chandramohan1* 1 London School of Hygiene and Tropical Medicine, London, United Kingdom, 2 Ghana Health Service, University of Ghana, Legon, Accra, Ghana, 3 Navrongo Health Research Centre, University of Ghana, Legon, Accra, Ghana, 4 School of Public Health, University of Ghana, Legon, Accra, Ghana, 5 University of Ghana Medical School, Korle-bu, Accra, Ghana Abstract Background: Malaria and anaemia are the leading causes of morbidity and mortality in children in sub-Saharan Africa. We have investigated the effect of intermittent preventive treatment with sulphadoxine-pyrimethamine or artesunate plus amodiaquine on anaemia and malaria in children in an area of intense, prolonged, seasonal malaria transmission in Ghana. Methods: 2451 children aged 3–59 months from 30 villages were individually randomised to receive placebo or artesunate plus amodiaquine (AS+AQ) monthly or bimonthly, or sulphadoxine-pyrimethamine (SP) bimonthly over a period of six months. The primary outcome measures were episodes of anaemia (Hb,8.0 g/dl) or malaria detected through passive surveillance. Findings: Monthly artesunate plus amodiaquine reduced the incidence of malaria by 69% (95% CI: 63%, 74%) and anaemia by 45% (95% CI: 25%,60%), bimonthly sulphadoxine-pyrimethamine reduced the incidence of malaria by 24% (95% CI: 14%,33%) and anaemia by 30% (95% CI: 6%, 49%) and bimonthly artesunate plus amodiaquine reduced the incidence of